Movement Alert|Intellia Therapeutics Intraday Rise 5.24% in Regular Trading, Phase 3 enrollment completion and reiterated Buy rating support sentiment

Market Focus
Nov 20

On November 20, Intellia Therapeutics rose 5.24% in Regular Trading, trading at $10.21/share, with turnover of $12.47 million. The move was linked to investor focus on the completion of enrollment in the MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv-PN, alongside a reiterated Buy rating and a $49 price target.

Earlier company updates said MAGNITUDE-2 enrollment had been completed and cash stood at $614.8 million, which management expects to fund operations at least into 2028. That support came despite weaker quarterly figures reported earlier this month, including EPS of $0.91 loss versus a $0.80 loss estimate and revenue of $7.163 million versus a $10.461 million estimate, leaving the stock caught between pipeline progress and near-term earnings pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10